| 43.46 -0.35 (-0.8%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 54.81 | 1-year : | 64.02 |
| Resists | First : | 46.93 | Second : | 54.81 |
| Pivot price | 42.31  |
|||
| Supports | First : | 39.68 | Second : | 35.2 |
| MAs | MA(5) : | 44.23  |
MA(20) : | 41.2 |
| MA(100) : | 47.36 |
MA(250) : | 56.69 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 77.4 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 91.83 | Low : | 26.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRAX ] has closed below upper band by 39.4%. Bollinger Bands are 43.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 44.02 - 44.38 | 44.38 - 44.62 |
| Low: | 40.92 - 41.3 | 41.3 - 41.56 |
| Close: | 42.94 - 43.56 | 43.56 - 43.97 |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Thu, 12 Jun 2025
Needham Reiterates Buy Rating on Praxis Precision Medicine (PRAX) with $80 Price Target | PRAX Stock News - GuruFocus
Wed, 04 Jun 2025
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 04 Jun 2025
Praxis Precision Medicines Strengthens Talent Acquisition with New RSU Grant Program - Stock Titan
Tue, 20 May 2025
Praxis Precision Medicines to Participate in Upcoming Conferences - Stock Titan
Mon, 05 May 2025
Clinical Trial Success: Praxis's DEE Drug Cuts Seizures by 90%, Eyes $3B Market Opportunity - Stock Titan
Fri, 02 May 2025
Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.57e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 1,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.3271e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 868.8 % |
| Return on Equity (ttm) | -40 % |
| Qtrly Rev. Growth | 8.12e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -24.26 |
| EBITDA (p.s.) | -6.79809e+007 |
| Qtrly Earnings Growth | -10.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -164 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.8 |
| Price to Cash Flow | 5.27 |
| Dividend | 0 |
| Forward Dividend | 1.88e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|